Recruiting
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
NCT07903415· Phase 1· Pfizer· Source
Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
NCT07824349· Phase 1· Juri Biosciences, Inc.· Source
Contact: Lisa Knapp
Recruiting
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
NCT07578649· Phase 3· Pfizer· Source
Recruiting
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
NCT07843940· Phase 1/2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006· Phase 1/2· Nurix Therapeutics, Inc.· Source
Recruiting
A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.
NCT07778498· Phase 1/2· Phrontline Biopharma· Source
Contact: Hamilton, Erika
Recruiting
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
NCT07683754· Phase 3· Daiichi Sankyo· Source
Contact: Principal Investigator
Recruiting
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
NCT07701941· Phase 1/2· Daiichi Sankyo· Source
Recruiting
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
NCT07637578· Phase 2· SCRI Development Innovations, LLC· Source
Contact: Hans Lee, MD (principal investigator)
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093· Phase 3· Nurix Therapeutics, Inc.· Source
Not yet recruiting
Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer
NCT07707674· Phase 1· Evopoint Biosciences Inc.· Source
Contact: New Patient Referrals
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035· Phase 1· Duboce Biopharmaceuticals, Inc.· Source
Contact: Lisa Knapp
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841· Phase 1· Compass Therapeutics· Source
Contact: Meredith Pelster, MD
Recruiting
A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
NCT07542704· Phase 1· Kumquat Biosciences Inc.· Source
Contact: Deepak Bhamidipati
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Contact: Communication Center
Recruiting
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
NCT07558733· Phase 1/2· Faeth Therapeutics· Source
Contact: Medical Monitor
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995· Phase 3· BioNTech SE· Source
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811· Phase 1· Janux Therapeutics· Source
Contact: Janux Therapeutics, MD
Recruiting
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855· Phase 1· Janssen Research & Development, LLC· Source
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655· Phase 1· Pfizer· Source
Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497· Phase 3· Bristol-Myers Squibb· Source
Contact: Melissa Johnson, Site 0240
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Meredith Pelster, Site 0417
Recruiting
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· Phase 1/2· Pfizer· Source
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source
Contact: AskSarah
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808· Phase 1· IDEAYA Biosciences· Source
Contact: Deepak Bhamidipati
Recruiting
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· Phase 1/2· Pfizer· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07325136· Phase 1/2· Bristol-Myers Squibb· Source
Contact: Melissa Johnson, Site 0006
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190· Phase 3· IDEAYA Biosciences· Source
Contact: Meredith McKean, MD Principal Investigator
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
NCT07195682· Phase 1· Bristol-Myers Squibb· Source
Contact: Benjamin Garmezy, Site 0026
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source
Contact: James Dean, MD, PhD
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916· Phase 1· Incyte Corporation· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Meredith Pelster, Site 0570
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232· Phase 3· Revolution Medicines, Inc.· Source
Contact: Revolution Medicines Study Director
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Contact: Benjamin Garmezy (principal investigator)
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181· Phase 1/2· Novelwise Pharmaceutical Corporation· Source
Contact: Annie Pai, PhD
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432· Phase 1/2· Vironexis Biotherapeutics Inc.· Source
Contact: SCRI Referrals
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Benjamin Garmezy, Site 0186
Recruiting
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
NCT07011576· Phase 2· SCRI Development Innovations, LLC· Source
Contact: Sarah Cannon Sarah Cannon Development Innovations, LLC
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499· Phase 1· Pfizer· Source
Recruiting
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT06974786· Phase 2· SCRI Development Innovations, LLC· Source
Contact: Hans Lee, MD (principal investigator)
Showing 50 of 133.